Non-fused Nonfullerene Acceptors with an Asymmetric Benzo[1,2-b:3,4-b', 6,5-b"]trithiophene (BTT) Donor Core and Different AcceptorTerminal Units for Organic Solar Cells.

Here in, we have designed two new unfused non-fullerene small molecules using asymmetric benzo[1,2-b:3.4-b', 6,5-b"]trithiophene (BTT) as the central donor core and different terminal units i. e.

The archaeal highly thermostable GH35 family β-galactosidase DaβGal has a unique seven domain protein fold.

The most extensively studied β-d-galactosidases (EC3.2.1.

Direct Determination of the Structure of Single Biopolymer Molecules Using Nanopore Sequencing.

This review highlights operational principles, features, and modern aspects of the development of third-generation sequencing technology of biopolymers focusing on the nucleic acids analysis, namely the nanopore sequencing system. Basics of the method and technical solutions used for its realization are considered, from the first works showing the possibility of creation of these systems to the easy-to-handle procedure developed by Oxford Nanopore Technologies company. Moreover, this review focuses on applications, which were developed and realized using equipment developed by the Oxford Nanopore Technologies, including assembly of whole genomes, methagenomics, direct analysis of the presence of modified bases.

Laparoscopic intracorporeal ileal ureter replacement: multi-institutional data from 102 patients.

Objective: To present long-term results of our laparoscopic intracorporeal ileal ureter replacement (LIUR) cohort, including more complex cases of laparoscopic ileocalycostomy.

Material And Methods: We collected records of patients undergoing LIUR. Follow-up included a chemical profile and urine cultures.

[Experience of using Experience of using NefroBest-N for rehabilitation of patients undergoing radical laparoscopic cystectomy].

Aim: To evaluate the efficacy and safety of NefroBest-N in patients undergoing to the radical cystectomy with neobladder formation.

Materials And Methods: A total of 60 patients with invasive bladder cancer aged 56 to 75 years, treated at A.I.